Ocular implant with stiffness qualities, methods of implantation and system

• US 10,531,983 B2
• Filed: 09/01/2017
• Issued: 01/14/2020
• Est. Priority Date: 01/28/2009
• Status: Active Grant

• Current Assignee: Alcon Incorporated
• Original Assignee: Novartis Ag
• Inventors: Silvestrini, Thomas A., de Juan, Jr., Eugene
• Primary Examiner(s): Severson, Ryan J.
• Application Number:
  US15/693,920
• Publication Number:
  US 20180071143A1
• Time in Patent Office: 865 Days
• CPC Class Codes: A61F 2210/0019 operated at only one temperature whilst inside or touching the human body, e.g. constrained in a non-operative shape during surgery, another temperature only occurring before the operation
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.

Claims

1. An ocular implant, comprising:

an elongate member having a proximal portion and a distal portion, at least one flow entry pathway located at the proximal portion of the elongate member, and at least one flow exit pathway in fluid communication with the at least one flow entry pathway, wherein the elongate member is adapted to be positioned in the eye such that the at least one flow entry pathway communicates with the anterior chamber, the at least one flow exit pathway communicates with the supraciliary space, and wherein the elongate member provides for aqueous fluid to flow from the anterior chamber toward the suprachoroidal space when the elongate member is implanted in the eye; and

wherein the elongate member comprises a material imparting a sufficient stiffness to the elongate member such that after implantation the elongate member is able to transition from a curved shape to a less curved shape to deform at least sub-scleral eye tissue so as to form a tented volume beneath the sclera.

2. The implant of claim 1, wherein the stiffness of the elongate member is greater than a stiffness of at least a portion of the eye tissue surrounding the supraciliary space.

3. The implant of claim 1, wherein the elongate member forms a straight chord relative to a curvature of the supraciliary space.

4. The implant of claim 1, wherein the eye tissue surrounding the supraciliary space comprises an outer tissue shell having a first boundary and a first curvature and an inner tissue shell having a second boundary and a second curvature, wherein the first curvature and the second curvature form a ratio wherein the stiffness of the elongate member changes the ratio between the first curvature and the second curvature.

5. The implant of claim 4, wherein the elongate member is curved such that it intersects, but does not conform to the first or second curvatures when implanted.

6. The implant of claim 1, wherein the wall material has a Young'"'"'s modulus that is less than 30,000 pounds per square inch.

7. The implant of claim 1, wherein the wall material has a Young'"'"'s modulus that is between about 30,000 pounds per square inch and 70,000 pounds per square inch.

8. The implant of claim 1, wherein the wall material has a Young'"'"'s modulus that is approximately 200,000 pounds per square inch.

9. The implant of claim 1, wherein the wall material has a Young'"'"'s modulus that is less than or equal to 40,000,000 pounds per square inch.

10. The implant of claim 1, wherein the elongate member further comprises an internal lumen.

11. The implant of claim 1, wherein the elongate member is configured such that a distal end of the elongate member presses against the sclera and a portion of the elongate member presses against and deforms the ciliary body to form the tented volume.